UroGen Pharma stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday.
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an 80 or higher RS Rating as they begin their largest runs.
Here Are 3 Keys For Successful Stock Investing
Is UroGen Pharma Stock A Buy?
UroGen Pharma stock is currently trading in a consolidation. While it's not currently an ideal time to invest, see if the biotech stock is able to offer and clear an appropriate buy point.
The biotech company reported 0% earnings growth in its most recent report, while sales growth came in at 9%.
UroGen Pharma stock earns the No. 112 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group.
